Zobrazeno 1 - 5
of 5
pro vyhledávání: '"E Roson Sanchez"'
Autor:
A. Arenaza Peña, C Gonzalez Perez, AA García Sacristán, E Roson Sanchez, JM Martínez Sesmero, MT Benitez Jimenez, MA Rodriguez Cabezas, J. A. Peña Pedrosa, A Liras Medina
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance The SARS-CoV-2 pandemic has highlighted the need to avoid exposure of patients to places with a high probability of transmission, such as hospitals Home delivery makes this possible, particularly in patients with disabilitie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c907c52567a742df2d591f2357c0c222
https://doi.org/10.1136/ejhpharm-2021-eahpconf.148
https://doi.org/10.1136/ejhpharm-2021-eahpconf.148
Autor:
M.L. Recio Blázquez, E Roson Sanchez, V. Puebla García, A. Pérez Morales, JM Martínez Sesmero
Publikováno v:
Section 2: Selection, Procurement and Distribution.
Background Solid oral dosage forms packed in multiple unit containers (SODF-MUC) are exposed, when the package is opened, to the hospital and patients’ home conditions (light, temperature, humidity and microbiological). Purpose To check the SODF–
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d528a9233691bb50335145ffdc30d5ee
https://doi.org/10.1136/ejhpharm-2019-eahpconf.76
https://doi.org/10.1136/ejhpharm-2019-eahpconf.76
Autor:
I Larrosa Espejo, JM Martínez Sesmero, JC Tallón Martínez, G Hernando Llorente, Zamora Barrios, E Roson Sanchez, M Molinero Muñoz, M.P. Pacheco Ramos, C González-Pérez, A. Arenaza Peña
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background Between 2016 and 2017 the National Agency of Medicines and Medical Devices regulated the use of nivolumab and pembrolizumab for the treatment of non-small-cell lung cancer (NSCLC). In clinical trials conducted, patients with ECOG 0–1 and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5b096b757c9604eedb7bb0532c48eebd
https://doi.org/10.1136/ejhpharm-2019-eahpconf.277
https://doi.org/10.1136/ejhpharm-2019-eahpconf.277
Autor:
G Hernando Llorente, M Molinero Muñoz, E Roson Sanchez, JM Martínez Sesmero, M Saenz de Tejada Lopez, C Tallon Martinez, I Larrosa Espejo
Publikováno v:
Section 5: Patient Safety and Quality Assurance.
Background Patients with a diagnosis of multiple myeloma (MM) have compromised innate and adaptive immunity, both humoral and cellular. The treatment of this pathology can produce immune alterations such as increasing the incidence of the Varicella
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0c0ea40c05c54787f5cf6338af44676c
https://doi.org/10.1136/ejhpharm-2019-eahpconf.486
https://doi.org/10.1136/ejhpharm-2019-eahpconf.486
Autor:
M.L. Recio Blázquez, M. Méndez Bailón, A. Santiago Pérez, P Pacheco Ramos, A. Nieto Sánchez, A. Pérez Morales, MI Borrego Hernando, E Roson Sanchez, I Larrosa Espejo, G Hernando Llorente
Publikováno v:
Eur J Hosp Pharm
Background The presence of a clinical pharmacist in the medical services has been shown in numerous previous publications as a great additional factor in the quality and safety of pharmacological treatment. In many hospitals there is still no clinica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ba69c8583c41d79f673ea636b140220
https://europepmc.org/articles/PMC7535782/
https://europepmc.org/articles/PMC7535782/
